Related Experiment Videos
Topical timolol and serum lipoproteins
1Department of Ophthalmology, Royal Hallamshire Hospital, Sheffield.
The British Journal of Ophthalmology
|November 1, 1990
Summary
Topical timolol, used for elevated intraocular pressure, does not significantly alter serum lipoprotein levels. This finding is important for patients on long-term therapy, suggesting lipid changes from oral timolol are not a concern for topical use.
Area of Science:
- Ophthalmology
- Cardiology
- Pharmacology
Background:
- Oral timolol, used for systemic hypertension, can negatively impact serum lipoprotein levels.
- Elevated intraocular pressure (IOP) is a significant risk factor for glaucoma.
- Beta-blockers are commonly prescribed for managing IOP and systemic hypertension.
Purpose of the Study:
- To investigate the effect of topical timolol on serum lipoprotein levels in patients with elevated intraocular pressure.
- To determine if topical timolol therapy poses similar lipid-altering risks as oral timolol.
Main Methods:
- A 15-week study involving 19 patients with elevated intraocular pressure.
- Patients received topical timolol therapy.
- Serum lipoprotein levels were monitored throughout the study period.
Main Results:
- Topical timolol therapy showed no significant adverse effects on serum lipoprotein levels.
- Lipid profiles remained stable in patients using topical timolol for elevated IOP.
Conclusions:
- Topical timolol is a safe option for managing elevated intraocular pressure regarding serum lipid profiles.
- Lipid changes associated with oral timolol should not influence the choice of topical beta-blockers for IOP management.
- This study provides reassurance for the widespread long-term use of topical timolol.